SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-056869
Filing Date
2024-05-09
Accepted
2024-05-09 16:05:10
Documents
62
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q fate-20240331.htm   iXBRL 10-Q 1992265
2 EX-31.1 fate-ex31_1.htm EX-31.1 11987
3 EX-31.2 fate-ex31_2.htm EX-31.2 12154
4 EX-32.1 fate-ex32_1.htm EX-32.1 8549
  Complete submission text file 0000950170-24-056869.txt   9039414

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT fate-20240331.xsd EX-101.SCH 1267988
66 EXTRACTED XBRL INSTANCE DOCUMENT fate-20240331_htm.xml XML 1833990
Mailing Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131
Business Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131 858.875.1803
FATE THERAPEUTICS INC (Filer) CIK: 0001434316 (see all company filings)

IRS No.: 651311552 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36076 | Film No.: 24930399
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)